PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.

CONCLUSION: These results should be confirmed in a larger patient cohort. PDE4 expression could be an effective potential prognostic factor and therapeutic target for patients with MDS and chronic myelomonocytic leukemia. The role of PDE4 inhibitors should be explored in vitro against MDS cell lines and in preclinical mouse models of MDS. PMID: 27521329 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27521329?dopt=Abstract

Source: Clinical Lymphoma and Myeloma - July 31, 2016 Category: Cancer & Oncology Authors: Chamseddine AN, Cabrero M, Wei Y, Ganan-Gomez I, Colla S, Takahashi K, Yang H, Bohannan ZS, Garcia-Manero G Tags: Clin Lymphoma Myeloma Leuk Source Type: research